Literature DB >> 7670533

GP 50/55, a membrane antigen of Trypanosoma cruzi involved in autoimmunity and immunosuppression.

C Hernández-Munaín1, J L De Diego, P Bonay, N Gironés, M Fresno.   

Abstract

Chagas' disease results from the infection of the protozoan parasite Trypanosoma cruzi and affects several million people in South America. Several alterations of the immune response have been described in this disease, such as severe immunosuppression of both cellular and humoral responses and the induction of autoantibodies crossreacting with host cells and tissues. We described here a GPI-linked 50/55 kDa antigen (GP50/55) present on the T. cruzi membrane, but not in the membrane of other parasites of the family Trypanosomatidae. We have obtained several monoclonal antibodies which specifically recognize this molecule. One of these GP50/55-specific mAbs (C10) crossreacts with a 28 kDa antigen expressed on the membrane of activated mouse and human T and B lymphocytes, after "in vitro" activation with mitogens, phorbol esters, or antigen, and on several murine T and B lymphocyte cell lines. Furthermore, this mAb was able to suppress mouse and human T and B cell proliferation to any of those stimuli. In addition, sera from T. cruzi-infected mice or Chagasic patients but not from uninfected mice or control patients contain antibodies which recognize a similar p28 antigen and also suppress the proliferation of human T lymphocytes. These results suggest a possible role of autoantibodies as an alternative mechanism for T. cruzi-associated immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7670533

Source DB:  PubMed          Journal:  Biol Res        ISSN: 0716-9760            Impact factor:   5.612


  4 in total

Review 1.  Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead.

Authors:  Kevin M Bonney; David M Engman
Journal:  Am J Pathol       Date:  2015-04-07       Impact factor: 4.307

2.  Utility of the Trypanosoma cruzi sequence database for identification of potential vaccine candidates by in silico and in vitro screening.

Authors:  Vandanajay Bhatia; Mala Sinha; Bruce Luxon; Nisha Garg
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

3.  Trypanosoma cruzi-induced immunosuppression: B cells undergo spontaneous apoptosis and lipopolysaccharide (LPS) arrests their proliferation during acute infection.

Authors:  E Zuñiga; C Motran; C L Montes; F L Diaz; J L Bocco; A Gruppi
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

4.  Trypanosoma cruzi P21: a potential novel target for chagasic cardiomyopathy therapy.

Authors:  Thaise Lara Teixeira; Fabrício Castro Machado; Aline Alves da Silva; Samuel Cota Teixeira; Bruna Cristina Borges; Marlus Alves Dos Santos; Flávia Alves Martins; Paula Cristina Brígido; Adele Aud Rodrigues; Ana Flávia Oliveira Notário; Bruno Antônio Ferreira; João Paulo Silva Servato; Simone Ramos Deconte; Daiana Silva Lopes; Veridiana Melo Rodrigues Ávila; Fernanda de Assis Araújo; Tatiana Carla Tomiosso; Marcelo José Barbosa Silva; Claudio Vieira da Silva
Journal:  Sci Rep       Date:  2015-11-17       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.